Skip to main
  1. Stocks
  2. Eton Pharmaceuticals Inc
  3. Forecast
ETON

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals is supported by a sharp commercial inflection, with 3Q26 revenue of $57.9M, up 158% year over year and 54% sequentially, while adjusted EBITDA reached $28.5M, or 49% of revenue, and gross margin expanded to 80%. The company’s HEMANGEOL relaunch is driving patient conversion and appears to be sustaining growth beyond the historical base, while management raised FY26 revenue guidance to more than $175M and lifted its adjusted EBITDA margin outlook to above 40%. Beyond the core franchise, LIBERVANT could open a new neurology market in 2027, the pipeline includes multiple late-stage programs with meaningful revenue potential, and $55.6M in cash plus positive operating cash flow strengthen balance-sheet flexibility.

Bears say

Eton Pharmaceuticals is facing a material development risk in ET-700, because while the drug showed a cleaner tolerability profile than GALZIN in a four-week, placebo-controlled pilot study of 36 healthy volunteers, its 12% reduction in hepatic copper uptake fell far short of GALZIN’s 46% and suggests inadequate pharmacologic effect. Management’s explanation that the release profile was too slow implies the current formulation may not reach the small intestine in time to block copper absorption, and the planned faster-release arms in 2027 likely delay a pivotal study start to late 2027 at the earliest. This combination of uncertain efficacy, formulation rework, and delayed development increases execution risk and weakens the investment case despite the favorable adverse-event profile.

ETON has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

ETON Analyst Forecast & Price Prediction

Get the latest ETON stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ETON

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 4 analysts, ETON has a Strong Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $75.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $75.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


ETON Analyst Forecast & Price Prediction

Get the latest ETON stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ETON

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ETON stock data and trends